Updated 2026-09 · 5 min read
Burn-S is a GLP-1 receptor agonist peptide. This guide reviews the mechanism of GLP-1 receptor agonism as reported in preclinical work and the STEP and SUSTAIN trial literature. It is a research-use compound and is not for use in humans or animals.
GLP-1 receptor agonism
GLP-1 is an incretin receptor central to insulin signaling and appetite-regulation pathways in research models. Single-receptor GLP-1 agonism is the most studied of the incretin mechanisms and the reference point against which the dual and triple agonists are compared.
Literature context
The GLP-1 agonist has been characterized across the STEP and SUSTAIN trial programs and extensive preclinical literature. It is summarized here as mechanism context only — no claim of safety, efficacy, or suitability for any use is made or implied.
In the catalog
This material is synthesized from publicly available preclinical literature and industry documentation for qualified laboratory researchers. It is not medical, veterinary, therapeutic, or diagnostic advice. All compounds are supplied and discussed solely for in-vitro laboratory research and are not for human or animal use.